Global sales information and US Prescriptions data of Interferon alpha 2b, Recombinant obtained from Centers for Medicare & Medicaid Services Website

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0INTERMEDIATES

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

Annual Reports

NA

21 RELATED EXCIPIENT COMPANIES

41EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Interferon alfa-2b, recombinant, 98530-12-2, Schembl6041041, Q4391540
Molecular Formula
C16H17Cl3I2N3NaO5S
Molecular Weight
746.5  g/mol
InChI Key
MIXCUJKCXRNYFM-UHFFFAOYSA-M

Interferon Alfa-2B
Alpha interferon encoded by the human IFNA2 gene. Recombinant forms are used in the treatment of CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; KAPOSI SARCOMA; MELANOMA; and HAIRY CELL LEUKEMIA.
1 2D Structure

Interferon Alfa-2B

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
sodium;diiodomethanesulfonate;N-propyl-N-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide
2.1.2 InChI
InChI=1S/C15H16Cl3N3O2.CH2I2O3S.Na/c1-2-4-20(15(22)21-5-3-19-10-21)6-7-23-14-12(17)8-11(16)9-13(14)18;2-1(3)7(4,5)6;/h3,5,8-10H,2,4,6-7H2,1H3;1H,(H,4,5,6);/q;;+1/p-1
2.1.3 InChI Key
MIXCUJKCXRNYFM-UHFFFAOYSA-M
2.1.4 Canonical SMILES
CCCN(CCOC1=C(C=C(C=C1Cl)Cl)Cl)C(=O)N2C=CN=C2.C(S(=O)(=O)[O-])(I)I.[Na+]
2.2 Synonyms
2.2.1 MeSH Synonyms

1. Ifn-alpha 2

2. Ifn-alpha-2

3. Ifnalpha 2b, Recombinant

4. Ifnalpha-2b, Recombinant

5. Interferon Alfa 2a

6. Interferon Alfa 2b

7. Interferon Alfa-2a

8. Interferon Alpha 2

9. Interferon Alpha 2b, Recombinant

10. Interferon Alpha A

11. Interferon Alpha-2

12. Interferon Alpha-2a, Recombinant

13. Interferon Alpha-2b, Recombinant

14. Interferon Alpha-a

15. Interferon-alpha 2

16. Intron A (interferon)

17. Leif A

18. Reaferon

19. Recombinant Ifnalpha-2b

20. Recombinant Interferon Alpha 2a

21. Recombinant Interferon Alpha 2b

22. Recombinant Interferon Alpha-2a

23. Recombinant Interferon Alpha-2b

24. Ro 22 8181

25. Ro 22-8181

26. Ro 228181

27. Roferon A

28. Roferon-a

29. Roferona

30. Sch 30500

31. Sch-30500

32. Sch30500

33. Viferon

2.2.2 Depositor-Supplied Synonyms

1. Interferon Alfa-2b, Recombinant

2. 98530-12-2

3. Schembl6041041

4. Q4391540

2.3 Create Date
2013-05-09
3 Chemical and Physical Properties
Molecular Weight 746.5 g/mol
Molecular Formula C16H17Cl3I2N3NaO5S
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count6
Rotatable Bond Count7
Exact Mass744.79416 g/mol
Monoisotopic Mass744.79416 g/mol
Topological Polar Surface Area113 Ų
Heavy Atom Count31
Formal Charge0
Complexity511
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count3
4 Drug and Medication Information
4.1 Therapeutic Uses

Recombinant Proteins; Interferon-alpha

National Library of Medicine's Medical Subject Headings online file (MeSH, 2013)


INTRON A is indicated for the treatment of patients 18 years of age or older with hairy cell leukemia. /Included in US product label/

US Natl Inst Health; DailyMed. Current Medication Information for INTRON A (interferon alfa-2b) kit (August 2012). Available from, as of August 2, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd653d74-48ab-49e4-a42d-ec1cbc59badb


INTRON A is indicated for the treatment of selected patients 18 years of age or older with AIDS-Related Kaposi's Sarcoma. The likelihood of response to INTRON A therapy is greater in patients who are without systemic symptoms, who have limited lymphadenopathy and who have a relatively intact immune system as indicated by total CD4 count. /Included in US product label/

US Natl Inst Health; DailyMed. Current Medication Information for INTRON A (interferon alfa-2b) kit (August 2012). Available from, as of August 2, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd653d74-48ab-49e4-a42d-ec1cbc59badb


INTRON A is indicated for the initial treatment of clinically aggressive follicular Non-Hodgkin's Lymphoma in conjunction with anthracycline-containing combination chemotherapy in patients 18 years of age or older. Efficacy of INTRON A therapy in patients with low-grade, low-tumor burden follicular Non-Hodgkin's Lymphoma has not been demonstrated. /Included in US product label/

US Natl Inst Health; DailyMed. Current Medication Information for INTRON A (interferon alfa-2b) kit (August 2012). Available from, as of August 2, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd653d74-48ab-49e4-a42d-ec1cbc59badb


For more Therapeutic Uses (Complete) data for Interferon Alfa-2b (17 total), please visit the HSDB record page.


4.2 Drug Warning

/BOXED WARNING/ Alpha interferons, including INTRON A, cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Patients with persistently severe or worsening signs or symptoms of these conditions should be withdrawn from therapy. In many but not all cases these disorders resolve after stopping INTRON A therapy.

US Natl Inst Health; DailyMed. Current Medication Information for INTRON A (interferon alfa-2b) kit (August 2012). Available from, as of August 2, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd653d74-48ab-49e4-a42d-ec1cbc59badb


Almost all patients experience adverse effects at some time during the course of interferon alfa therapy. However, evaluation of some adverse effects and establishment of a causal relationship to interferon alfa have been difficult since the drug has been used principally in patients with serious underlying diseases, such as acquired immunodeficiency syndrome (AIDS), various cancers, and/or viral hepatitis.

American Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 1072


A flu-like syndrome develops to some degree in almost all patients receiving 1 million units or more of interferon alfa but its severity appears to be dose related. The syndrome is characterized by the development of fever (in about 40-98% of patients), fatigue/malaise (in about 50-95% of patients), myalgia (in about 30-75% of patients), chills (in about 40-65% of patients), headache (in about 20-70% of patients), arthralgia (in about 5-24% of patients), rigors, tachycardia, anorexia, dry mouth, dysgeusia, back pain, sweating, and dizziness. Abdominal cramps and diarrhea also may be associated with the syndrome.

American Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 1072


Myalgia and arthralgia, often associated with a flu-like syndrome, are the most frequent adverse musculoskeletal effects of interferon alfa, occurring in up to 70 and 24% of patients, respectively. These effects generally are transient, mild, and self-limiting. More severe myalgias, generally involving the lower extremities and associated with limitation of movement, have been observed in patients with chronic myelogenous leukemia receiving the drug. Such myalgias frequently require 1-2 weeks of bed rest and corticosteroid and/or analgesic (e.g., opiate) therapy for relief. These severe myalgias generally were not associated with an increase in serum muscle enzymes, and electromyograms have failed to reveal evidence of myositis. Skeletal pain, which frequently is one of the first adverse effects associated with interferon alfa therapy, has been reported in some patients with multiple myeloma who were receiving the drug; however, arthralgias were not observed in patients with metastatic osseous lesions associated with renal cell carcinoma or other malignancies.

American Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 1073


For more Drug Warnings (Complete) data for Interferon Alfa-2b (47 total), please visit the HSDB record page.


4.3 Drug Indication

For the treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma.


FDA Label


* Chronic hepatitis B:

Treatment of adult patients with chronic hepatitis B associated with evidence of hepatitis-B viral replication (presence of DNA of hepatitis-B virus (HBV-DNA) and hepatitis-B antigen (HBeAg), elevated alanine aminotransferase (ALT) and histologically proven active liver inflammation and / or fibrosis.

* Chronic hepatitis C:

Before initiating treatment with IntronA, consideration should be given to the results from clinical trials comparing IntronA with pegylated interferon.

Adult patients

IntronA is indicated for the treatment of adult patients with chronic hepatitis C who have elevated transaminases without liver decompensation and who are positive for hepatitis-C virus-RNA (HCV-RNA).

The best way to use IntronA in this indication is in combination with ribavirin.

Children three years of age and older and adolescents

IntronA is indicated, in a combination regimen with ribavirin, for the treatment of children three years of age and older and adolescents, who have chronic hepatitis C, not previously treated, without liver decompensation, and who are positive for HCV-RNA. When deciding not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition that resulted in reduced final adult height in some patients.

The decision to treat should be made on a case-by-case basis.

* Hairy-cell leukaemia:

Treatment of patients with hairy cell leukaemia.

* Chronic myelogenous leukaemia:

Monotherapy

Treatment of adult patients with Philadelphia-chromosome- or bcr/abl-translocation-positive chronic myelogenous leukaemia.

Clinical experience indicates that a haematological and cytogenetic major / minor response is obtainable in the majority of patients treated. A major cytogenetic response is defined by < 34 % Ph+ leukaemic cells in the bone marrow, whereas a minor response is 34 %, but < 90 % Ph+ cells in the marrow.

Combination therapy

The combination of interferon alfa-2b and cytarabine (Ara-C) administered during the first 12 months of treatment has been demonstrated to significantly increase the rate of major cytogenetic responses and to significantly prolong the overall survival at three years when compared to interferon alfa-2b monotherapy.

* Multiple myeloma:

As maintenance therapy in patients who have achieved objective remission (more than 50% reduction in myeloma protein) following initial induction chemotherapy.

Current clinical experience indicates that maintenance therapy with interferon alfa-2b prolongs the plateau phase; however, effects on overall survival have not been conclusively demonstrated.

* Follicular lymphoma:

Treatment of high-tumour-burden follicular lymphoma as adjunct to appropriate combination induction chemotherapy such as a CHOP-like regimen. High tumour burden is defined as having at least one of the following: bulky tumour mass (> 7 cm), involvement of three or more nodal sites (each > 3 cm), systemic symptoms (weight loss > 10 %, pyrexia > 38C for more than eight days, or nocturnal sweats), splenomegaly beyond the umbilicus, major organ obstruction or compression syndrome, orbital or epidural involvement, serous effusion, or leukaemia.

* Carcinoid tumour:

Treatment of carcinoid tumours with lymph node or liver metastases and with 'carcinoid syndrome'.

* Malignant melanoma:

As adjuvant therapy in patients who are free of disease after surgery but are at high risk of systemic recurrence, e. g. patients with primary or recurrent (clinical or pathological) lymph-node.


* Chronic Hepatitis B: :

Treatment of adult patients with chronic hepatitis B associated with evidence of hepatitis B viral replication (presence of HBV-DNA and HBeAg), elevated alanine aminotransferase (ALT) and histologically proven active liver inflammation and/or fibrosis.

* Chronic Hepatitis C: :

Adult patients:

IntronA is indicated for the treatment of adult patients with chronic hepatitis C who have elevated transaminases without liver decompensation and who are positive for serum HCV-RNA or anti-HCV (see section 4. 4).

The best way to use IntronA in this indication is in combination with ribavirin.

Chidren and adolescents:

IntronA is intended for use, in a combination regimen with ribavirin, for the treatment of children and adolescents 3 years of age and older, who have chronic hepatitis C, not previously treated, without liver decompensation, and who are positive for serum HCV-RNA. The decision to treat should be made on a case by case basis, taking into account any evidence of disease progression such as hepatic inflammation and fibrosis, as well as prognostic factors for response, HCV genotype and viral load. The expected benefit of treatment should be weighed against the safety findings observed for paediatric subjects in the clinical trials (see sections 4. 4, 4. 8 and 5. 1).


5 Pharmacology and Biochemistry
5.1 Pharmacology

Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R.


5.2 MeSH Pharmacological Classification

Antineoplastic Agents

Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)


Antiviral Agents

Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)


5.3 FDA Pharmacological Classification
5.3.1 Pharmacological Classes
Interferon-alpha [CS]; Interferon alpha [EPC]
5.4 ATC Code

L03AB05


L03AB05


L - Antineoplastic and immunomodulating agents

L03 - Immunostimulants

L03A - Immunostimulants

L03AB - Interferons

L03AB05 - Interferon alfa-2b


5.5 Absorption, Distribution and Excretion

Absorption

Absorption is high (greater than 80%) when administered intramuscularly or subcutaneously.


For systemic effects, interferon alfa is administered parenterally because the drug is susceptible to degradation by proteolytic enzymes in the GI tract. Interferon alfa is well absorbed following IM or subcutaneous injection; the apparent fraction of the dose absorbed after IM or subcutaneous injection exceeds 80%. Peak serum interferon alfa concentrations following IV administration of the drug generally occur within 15-60 minutes and are substantially greater than those attained after IM or subcutaneous administration. However, serum interferon alfa concentrations following IM or subcutaneous administration generally are maintained for longer periods of time than those produced by rapid IV injection or rapid (e.g., 40 minutes or less) IV infusion.

American Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 1084


After intravenous administration, serum INTRON A concentrations peaked (135-273 IU/mL) by the end of the 30-minute infusion, then declined at a slightly more rapid rate than after intramuscular or subcutaneous drug administration, becoming undetectable 4 hours after the infusion.

US Natl Inst Health; DailyMed. Current Medication Information for INTRON A (interferon alfa-2b) kit (August 2012). Available from, as of August 2, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd653d74-48ab-49e4-a42d-ec1cbc59badb


The pharmacokinetics of INTRON A were studied in 12 healthy male volunteers following single doses of 5 million IU/sq m administered intramuscularly, subcutaneously, and as a 30-minute intravenous infusion in a crossover design. The mean serum INTRON A concentrations following intramuscular and subcutaneous injections were comparable. The maximum serum concentrations obtained via these routes were approximately 18 to 116 IU/mL and occurred 3 to 12 hours after administration. Serum concentrations were undetectable by 16 hours after the injections.

US Natl Inst Health; DailyMed. Current Medication Information for INTRON A (interferon alfa-2b) kit (August 2012). Available from, as of August 2, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd653d74-48ab-49e4-a42d-ec1cbc59badb


Limited data on the tissue distribution of interferon in animals suggest that mixtures of naturally occurring human or animal interferons are widely and rapidly distributed into body tissues after parenteral administration, with the highest concentrations occurring in spleen, kidney, liver, and lung.

American Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 1084


For more Absorption, Distribution and Excretion (Complete) data for Interferon Alfa-2b (7 total), please visit the HSDB record page.


5.6 Biological Half-Life

The elimination half-life following both intramuscular and subcutaneous injections was approximately 2 to 3 hours. The elimination half-life was approximately 2 hours following intravenous injection.


The elimination half-life was approximately 2 hours /after intravenous administration/.

US Natl Inst Health; DailyMed. Current Medication Information for INTRON A (interferon alfa-2b) kit (August 2012). Available from, as of August 2, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd653d74-48ab-49e4-a42d-ec1cbc59badb


The elimination half-life of INTRON A following both intramuscular and subcutaneous injections was approximately 2 to 3 hours.

US Natl Inst Health; DailyMed. Current Medication Information for INTRON A (interferon alfa-2b) kit (August 2012). Available from, as of August 2, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd653d74-48ab-49e4-a42d-ec1cbc59badb


5.7 Mechanism of Action

Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which upon dimerization activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.


Interferons exert their cellular activities by binding to specific membrane receptors on the cell surface. Once bound to the cell membrane, interferons initiate a complex sequence of intracellular events. In vitro studies demonstrated that these include the induction of certain enzymes, suppression of cell proliferation, immunomodulating activities such as enhancement of the phagocytic activity of macrophages and augmentation of the specific cytotoxicity of lymphocytes for target cells, and inhibition of virus replication in virus-infected cells.

US Natl Inst Health; DailyMed. Current Medication Information for INTRON A (interferon alfa-2b) kit (August 2012). Available from, as of August 2, 2013: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fd653d74-48ab-49e4-a42d-ec1cbc59badb


Following binding to specific cellular receptors, interferons (INFs) activate the JAK_STAT signal-transduction pathway and lead to the nuclear translocation of a cellular protein complex that binds to genes containing an INF-specific response element. This, in turn, leads to the synthesis of over two dozen proteins that contribute to viral resistance mediated at different stages of viral penetration. Inhibition of protein synthesis is the major inhibitory effect for many viruses. INF-induced proteins include 2',5'-oligoadenylate (2-5(A)) synthetase and a protein kinase, either of which can inhibit protein synthesis in the presence of double stranded RNA. The 2-5(A) synthetase produces adenylate oligomers that activate a latent cellular endoribonuclease (RNase L) to cleave both cellular and viral single stranded RNAs. The protein kinase selectively phosphorylates and inactivates a protein involved in protein synthesis, eukaryotic initiation factor 2 (eIF-2). IFN-induced protein kinase also may be an important effector of apoptosis. In addition, INF induces a phosphodiesterase that cleaves a portion of transfer RNA and thus prevents peptide elongation.

Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill, 2006., p. 1261


The precise mechanisms of action of interferons have not been fully elucidated but appear to be complex, and the resultant activities appear to be substantially interrelated. Unlike classic antiviral and cytotoxic agents, the antiviral and antineoplastic properties of interferons appear to result from a complex cascade of biologic modulation and pharmacologic effects rather than from direct virucidal or cytocidal effects. The drugs affect many cell functions producing restoration, augmentation, and/or modulation of the host's immune system; direct antiproliferative and antineoplastic activities; modulation of cell differentiation; and modulation of cellular transcription and translation, including a reduction in oncogene expression. Some or all of these effects may be interrelated and ultimately responsible for the antiviral and antineoplastic activity of interferons. Interferons must bind to specific cell surface receptors in order to exert biologic and pharmacologic effects (e.g., antiviral activity); such binding appears to involve high-affinity sites. In addition, some evidence suggests that the principal effects of interferons result not from direct intracellular actions but rather from ligand-receptor complexes at the cell surface that can mediate and induce intracellular events.

American Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 1080


USDMF

read-more
read-more

01

Aim Immunotech Inc

U.S.A

USDMF

arrow
26th North American ISSX
Not Confirmed

01

26th North American ISSX
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 27142

Submission : 1980-10-31

Status : Inactive

Type : II

blank

02

Aim Immunotech Inc

U.S.A

USDMF

arrow
26th North American ISSX
Not Confirmed

02

26th North American ISSX
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 18614

Submission : 1992-10-22

Status : Inactive

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

JDMF

read-more
read-more

01

26th North American ISSX
Not Confirmed
arrow
arrow
26th North American ISSX
Not Confirmed

Interferon-α “Hayashibara” HSA-free

Registration Number : 217MF10026

Registrant's Address : 1-2-3 Shimoishii, Kita-ku, Okayama City

Initial Date of Registration : 2005-05-18

Latest Date of Registration : 2006-04-07

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-more

01

26th North American ISSX
Not Confirmed
arrow
arrow
26th North American ISSX
Not Confirmed

INTERFERON ALFA-2B

NDC Package Code : 53713-0079

Start Marketing Date : 1986-06-04

End Marketing Date : 2024-12-31

Dosage Form (Strength) : INJECTION, POWDER, FOR SOLUTION (69ug/1)

Marketing Category : DRUG FOR FURTHER PROCESSING

blank

02

26th North American ISSX
Not Confirmed
arrow
arrow
26th North American ISSX
Not Confirmed

INTERFERON ALFA-2B

NDC Package Code : 53713-0078

Start Marketing Date : 1986-06-04

End Marketing Date : 2024-12-31

Dosage Form (Strength) : INJECTION, POWDER, FOR SOLUTION (38ug/1)

Marketing Category : DRUG FOR FURTHER PROCESSING

blank

03

26th North American ISSX
Not Confirmed
arrow
arrow
26th North American ISSX
Not Confirmed

INTERFERON ALFA-2B

NDC Package Code : 53713-0080

Start Marketing Date : 1986-06-04

End Marketing Date : 2024-12-31

Dosage Form (Strength) : INJECTION, POWDER, FOR SOLUTION (192ug/1)

Marketing Category : DRUG FOR FURTHER PROCESSING

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

Biotechnica DWC

Algeria
26th North American ISSX
Not Confirmed
arrow

Biotechnica DWC

Algeria
arrow
26th North American ISSX
Not Confirmed

Interferon Alfa-2B

About the Company : BIOTECHNICA DWC LLC has carved a niche for itself in providing value added compliance, regulatory qualification, project management and GDP guidance services to pharma companies al...

BIOTECHNICA DWC LLC has carved a niche for itself in providing value added compliance, regulatory qualification, project management and GDP guidance services to pharma companies all over the world. Biotechnica is an integrated global solution provider from design to implementation of industrial projects in the areas of Pharmaceuticals,Agri-food ,Cosmetics and Nutrition. With more than 25 years of experience in the assembly of plants, particularly in the pharmaceutical sector, we accompany our customers in the various stages of their projects – E-CTD Dossieers – Raw Materiels – Equipements – Accessories – Packaging – Distribution.
blank

02

KinBio

Israel
26th North American ISSX
Not Confirmed
arrow

KinBio

Israel
arrow
26th North American ISSX
Not Confirmed

Interferon Alfa-2B

About the Company : KinBio is a rapidly growing biopharmaceutical company based in Rehovot, Israel, with its main focus on developing needed therapies as well as offering a wide range of CDMO services...

KinBio is a rapidly growing biopharmaceutical company based in Rehovot, Israel, with its main focus on developing needed therapies as well as offering a wide range of CDMO services – from concept to product. KinBio’s main focus is to pursue opportunities in the global pharmaceutical market. Augmented by a global group of affiliated companies, Kinbio specializes in research, development, manufacturing and commercialization of biopharmaceutical products. Kinbio’s commitment to top standard quality is inherent across the entire global organization, from our FDA approved cGMP sites to our state of the art R&D laboratories.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

The data showed positive safety, tolerability and biological activity of a 13-day dosing regimen conducted in Q2 2021 for intranasal Ampligen® (rintatolimod) in healthy subjects.


Lead Product(s): Rintatolimod,Interferon Alfa-2B

Therapeutic Area: Infections and Infectious Diseases Product Name: Ampligen

Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 08, 2022

blank

01

26th North American ISSX
Not Confirmed
26th North American ISSX
Not Confirmed

Details : The data showed positive safety, tolerability and biological activity of a 13-day dosing regimen conducted in Q2 2021 for intranasal Ampligen® (rintatolimod) in healthy subjects.

Product Name : Ampligen

Product Type : Large molecule

Upfront Cash : Not Applicable

December 08, 2022

blank

Details:

Ampligen is AIM’s dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen has demonstrated in the clinic the potential for standalone efficacy in a number of solid tumors.


Lead Product(s): Rintatolimod,Interferon Alfa-2B,Paclitaxel

Therapeutic Area: Oncology Product Name: Ampligen

Highest Development Status: Phase IProduct Type: Large molecule

Partner/Sponsor/Collaborator: Roswell Park Comprehensive Cancer Center

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 14, 2022

blank

02

26th North American ISSX
Not Confirmed
26th North American ISSX
Not Confirmed

Details : Ampligen is AIM’s dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen has demonstrated in the clinic the potential for standalon...

Product Name : Ampligen

Product Type : Large molecule

Upfront Cash : Not Applicable

November 14, 2022

blank

Details:

Ampligen (rintatolimod) is AIM’s dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system.


Lead Product(s): Rintatolimod,Interferon Alfa-2B,Celecoxib

Therapeutic Area: Oncology Product Name: Ampligen

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Roswell Park Comprehensive Cancer Center

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 30, 2022

blank

03

26th North American ISSX
Not Confirmed
26th North American ISSX
Not Confirmed

Details : Ampligen (rintatolimod) is AIM’s dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system.

Product Name : Ampligen

Product Type : Small molecule

Upfront Cash : Not Applicable

August 30, 2022

blank

Details:

The preliminary data from uncontrolled clinical trial found that patients reported statistically significant improvements in chronic fatigue after treatment with an immuno-modulator Ampligen (rintatolimod).


Lead Product(s): Rintatolimod,Interferon Alfa-2B

Therapeutic Area: Infections and Infectious Diseases Product Name: Ampligen

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 28, 2022

blank

04

26th North American ISSX
Not Confirmed
26th North American ISSX
Not Confirmed

Details : The preliminary data from uncontrolled clinical trial found that patients reported statistically significant improvements in chronic fatigue after treatment with an immuno-modulator Ampligen (rintatolimod).

Product Name : Ampligen

Product Type : Small molecule

Upfront Cash : Not Applicable

July 28, 2022

blank

Details:

Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with metastatic and locally advanced pancreatic cancer (LAPC).


Lead Product(s): Rintatolimod,Interferon Alfa-2B,Celecoxib

Therapeutic Area: Oncology Product Name: Ampligen

Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 20, 2022

blank

05

26th North American ISSX
Not Confirmed
26th North American ISSX
Not Confirmed

Details : Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with metastatic and locally advanced pancreatic cancer (LAPC).

Product Name : Ampligen

Product Type : Small molecule

Upfront Cash : Not Applicable

July 20, 2022

blank

Details:

Ampligen® (rintatolimod), is an immuno-modulator with broad spectrum activity being developed for globally important cancers, viral diseases and disorders of the immune system.


Lead Product(s): Rintatolimod,Interferon Alfa-2B

Therapeutic Area: Infections and Infectious Diseases Product Name: Ampligen

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 18, 2022

blank

06

26th North American ISSX
Not Confirmed
26th North American ISSX
Not Confirmed

Details : Ampligen® (rintatolimod), is an immuno-modulator with broad spectrum activity being developed for globally important cancers, viral diseases and disorders of the immune system.

Product Name : Ampligen

Product Type : Small molecule

Upfront Cash : Not Applicable

May 18, 2022

blank

Details:

Ampligen (rintatolimod) sterile solution is indicated for the treatment of severely debilitated patients with chronic fatigue syndrome (cfs) who have been diagnosed for longer than one year.


Lead Product(s): Rintatolimod,Interferon Alfa-2B,Paclitaxel

Therapeutic Area: Oncology Product Name: Ampligen

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 24, 2022

blank

07

26th North American ISSX
Not Confirmed
26th North American ISSX
Not Confirmed

Details : Ampligen (rintatolimod) sterile solution is indicated for the treatment of severely debilitated patients with chronic fatigue syndrome (cfs) who have been diagnosed for longer than one year.

Product Name : Ampligen

Product Type : Small molecule

Upfront Cash : Not Applicable

March 24, 2022

blank

Details:

AP-003 is an anti-viral, recombinant human interferon alpha-2b product proven to be an effective treatment against COVID-19 successfully completed the Phase 1 portion of the Phase 1-2 randomized placebo controlled trial.


Lead Product(s): Interferon Alfa-2B

Therapeutic Area: Infections and Infectious Diseases Product Name: AP-003

Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 29, 2021

blank

08

26th North American ISSX
Not Confirmed
26th North American ISSX
Not Confirmed

Details : AP-003 is an anti-viral, recombinant human interferon alpha-2b product proven to be an effective treatment against COVID-19 successfully completed the Phase 1 portion of the Phase 1-2 randomized placebo control...

Product Name : AP-003

Product Type : Large molecule

Upfront Cash : Not Applicable

November 29, 2021

blank

Details:

Studies are ongoing to validate preliminary results and to test rhIFN⍺2b activity against Gamma (Brazil), Lambda (Peru), and the recent C.1.2 (South Africa) variant which contains mutations associated with increased transmissibility and the ability to evade antibodies therapy.


Lead Product(s): Interferon Alfa-2B

Therapeutic Area: Infections and Infectious Diseases Product Name: AP-003

Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 12, 2021

blank

09

26th North American ISSX
Not Confirmed
26th North American ISSX
Not Confirmed

Details : Studies are ongoing to validate preliminary results and to test rhIFN⍺2b activity against Gamma (Brazil), Lambda (Peru), and the recent C.1.2 (South Africa) variant which contains mutations associated with in...

Product Name : AP-003

Product Type : Large molecule

Upfront Cash : Not Applicable

October 12, 2021

blank

Details:

The trial tests BetterLife’s proprietary inhaled interferon alpha-2b product, AP-003 administered via nebulizer. AP-003, being a Type I interferon, is a broad acting antiviral agent used in COVID-19 patients.


Lead Product(s): Interferon Alfa-2B

Therapeutic Area: Infections and Infectious Diseases Product Name: AP-003

Highest Development Status: PreclinicalProduct Type: Large molecule

Partner/Sponsor/Collaborator: Pontificia Universidad Catolica de Chile

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 22, 2021

blank

10

26th North American ISSX
Not Confirmed
26th North American ISSX
Not Confirmed

Details : The trial tests BetterLife’s proprietary inhaled interferon alpha-2b product, AP-003 administered via nebulizer. AP-003, being a Type I interferon, is a broad acting antiviral agent used in COVID-19 patients.

Product Name : AP-003

Product Type : Large molecule

Upfront Cash : Not Applicable

September 22, 2021

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

read-more
read-more

01

26th North American ISSX
Not Confirmed
arrow
arrow
26th North American ISSX
Not Confirmed

Interferon Alfa-2B

Brand Name : Alfaferone

Dosage Form : Interferon Alfa N3 3.000.000Iu 1 Unit Parenteral Use

Dosage Strength : 1 vial IM SC EV 3,000,000 IU 1 ml

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Italy

blank

02

26th North American ISSX
Not Confirmed
arrow
arrow
26th North American ISSX
Not Confirmed

interferon alfa-2b

Brand Name : Viraferon

Dosage Form : INJEKTIONSVÄTSKA, LÖSNING

Dosage Strength : 25 MILJ IE

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

blank

03

26th North American ISSX
Not Confirmed
arrow
arrow
26th North American ISSX
Not Confirmed

interferon alfa-2b

Brand Name : Viraferon

Dosage Form : INJEKTIONSVÄTSKA, LÖSNING

Dosage Strength : 5 MILJ IE

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

blank

04

26th North American ISSX
Not Confirmed
arrow
arrow
26th North American ISSX
Not Confirmed

Interferon Alfa-2B

Brand Name : Roceron

Dosage Form : Injection fluid, resolution

Dosage Strength : 18 Mill IE/ml

Packaging : Finish filled syringe of glass

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

05

26th North American ISSX
Not Confirmed
arrow
arrow
26th North American ISSX
Not Confirmed

interferon alfa-2b

Brand Name : IntronA

Dosage Form : SOLUTION FOR INJECTION

Dosage Strength : 3 MILLION IU

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

blank

06

26th North American ISSX
Not Confirmed
arrow
arrow
26th North American ISSX
Not Confirmed

interferon alfa-2b

Brand Name : IntronA (multidose)

Dosage Form : SOLUTION FOR INJECTION

Dosage Strength : 60 MILLION IU

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

blank

07

26th North American ISSX
Not Confirmed
arrow
arrow
26th North American ISSX
Not Confirmed

peginterferon alfa-2b

Brand Name : PegIntron

Dosage Form : POWDER AND SOLVENT FOR SOLUTION FOR INJECTION

Dosage Strength : 150 MICROGRAM

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

blank

08

26th North American ISSX
Not Confirmed
arrow
arrow
26th North American ISSX
Not Confirmed

peginterferon alfa-2b

Brand Name : PegIntron

Dosage Form : POWDER AND SOLVENT FOR SOLUTION FOR INJECTION

Dosage Strength : 100 MICROGRAMS

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

blank

09

26th North American ISSX
Not Confirmed
arrow
arrow
26th North American ISSX
Not Confirmed

peginterferon alfa-2b

Brand Name : ViraferonPeg

Dosage Form : PULVER OCH VÄTSKA TILL INJEKTIONSVÄTSKA

Dosage Strength : 50 MIKROGRAM

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

blank

10

26th North American ISSX
Not Confirmed
arrow
arrow
26th North American ISSX
Not Confirmed

peginterferon alfa-2b

Brand Name : ViraferonPeg

Dosage Form : PULVER OCH VÄTSKA TILL INJEKTIONSVÄTSKA

Dosage Strength : 80 MIKROGRAM

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Solubilizers

read-more
read-more

Parenteral

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Topical

read-more
read-more

Emulsifying Agents

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Taste Masking

read-more
read-more

Surfactant & Foaming Agents

read-more
read-more

Coating Systems & Additives

read-more
read-more

Co-Processed Excipients

read-more
read-more

Direct Compression

read-more
read-more

Rheology Modifiers

read-more
read-more

API Stability Enhancers

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty